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Concise summary
A preponderance of data reported in the literature
supports the use of multimodality therapy for the
treatment gastroesophageal junction (GEJ) adeno-
carcinomas, albeit largely by extrapolation. When
distinguished by tumor location, major therapeutic
differences largely result from the extent of tumor
resection, rather from any differences in neoadju-
vant or adjuvant treatment regimens. Perioperative
treatment, either chemotherapy or chemotherapy
with concurrent radiation therapy, provided a statis-
tically significant overall survival benefit compared
to resection alone for esophagogastric carcinomas,
with a hazard ratio of 0.81 favoring combined
modality therapy. Although the benefit of any peri-
operative treatment regimen was less apparent for
patientswith esophageal cancers, with a hazard ratio
of 0.87, a cohort of patients, consisting predomi-
nantly of those with esophageal or GEJ carcinomas
that had received preoperative chemoradiation, was
found to have a survival benefit, with a hazard ratio
of 0.70. Perioperative treatment regimens predom-
inantly include platinum-based chemotherapy,
regardless of site of tumor origin, and are consid-
ered for more advanced-stage tumors. For Siewert
type II or type III adenocarcinomas, perioperative
chemotherapy without radiation therapy is typ-
ically recommended, whereas for more proximal
tumors (type I or type II), concurrent radiation
therapy can be administered preoperatively with
carboplatin and paclitaxel.
There have been many randomized trials of pre-
operative chemoradiotherapy (CRT) versus surgery
alone. The largest and most recent trial is the
CROSS study that randomized patients with either
doi: 10.1111/nyas.12532
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squamous cell carcinoma (SCC)or adenocarcinoma
to either surgery alone or preoperative CRT. The
CRT regimen was extremely well tolerated, and al-
though the postoperative complication rates were
somewhat higher than expected, there were no sig-
nificant differences between the two groups. The
principal study supporting the use of preoperative
chemotherapy for esophageal cancer is the Medi-
cal Research Council oestradiol (OE2) trial. With
a median follow-up of 37 months, the 2-year sur-
vivals were 43% for preoperative chemotherapy ver-
sus 34% for surgery alone (P = 0.004). In a trial
comparing CRT versus chemotherapy, because the
study was closed early before reaching its target ac-
crual, the improved survival with CRT did not reach
statistical significance.
Currently recognized prognostic or predictive
markers have clear evidentiary support for their use
in the emerging practice of personalized medicine.
In both esophageal adenocarcinoma (EAC) and
squamous cell cancer, recent exomic and genomic
sequencing analyses have strengthened the objective
foundation for the importance of selectedmolecular
pathways to the genesis and progression of disease.
In adenocarcinoma, a variety ofmolecular pathways
have been targeted for molecular analysis and clin-
ical intervention. The most important in current
practice is MAP kinase, associated with tyrosine ki-
nase receptors and downstream effectors through
KRAS and BRAF. The two most common are HER2
and EGFR. The importance of the pTEN tumor
suppressor, through its inhibitory effects on the
PI3K–Akt–mTORpathway, has been independently
established in a subset of EAC. The role of small-
molecule inhibitors in counteracting the molecu-
lar effects of epigenetic alterations in the canonical
Wnt signaling pathway is also intriguing, when in-
terventions for adenocarcinoma and squamous cell
cancer are compared to those proposed for cancer
models more dependent on mutational alterations
in the pathway. Notch signaling is also potentially
important to both adenocarcinoma and squamous
cell cancer, with loss of SMAD4 inhibition seen in
adenocarcinoma and loss of function due to muta-
tion in squamous cell cancer. Several constraints,
including the degree of heterogeneity for these
markers within target populations and the as yet
poorly understood nature of the interactions of dif-
ferent functional pathways on treatable foci, com-
plicate the attempts to determine the relative impor-
tance of a given biomarker to both risk assessment
and patient management.
Early identification of pathological complete re-
sponse (pCR) or pathological non-response (pNR)
during or after neoadjuvant treatment is of clini-
cal importance to reduce toxicity and improve per-
sonalized patient care. Negative predictive values
of a test are of particular interest, as these refer to
the likeliness of a suspected complete response––
based on the test result in an individual patient––
to truly reflect pCR. Current imaging lacks accurate
assessment of response to neoadjuvant treatment in
esophageal cancer. At the UniversityMedical Center
Utrecht (the Netherlands), the PRIOR trial (PRe-
operative Identification Of Response to neoadju-
vant chemo-radiotherapy for esophageal cancer) is
designed as an explorative single-center diagnostic
study to assess both the distinct and combined value
of advancedMRI and PET–CT scanning in the eval-
uation of treatment response to neoadjuvant CRT
for patients with esophageal cancer.
No generally accepted standardized clinical or
histopathological response evaluation system fol-
lowing treatment has been established so far. Tumor
regression-grade analysis as a marker of response
was undertaken in previous studies and scored from
complete regression to absent regression. It remains
a significantpredictorof disease-free survival (DFS),
although it suffers from high inter-observer vari-
ability. The three-tiered tumor regression scoring
system seems to be more easily implemented, more
reproducible, stronger, and clearer with regard to
prognostic impact. It may provide highly valuable
prognostic information, whichmay even exceed the
prognostic impact of the current TNM classifica-
tion.
The role of ABC transporters in the mechanism
of multiple drug resistance (MDR) to most antitu-
mor agents used in the clinical practice has been
scientifically proven. The influence of cisplatin and
carboplatin on intracellular accumulation of the
model MDR drug doxorubicin in multiple drug-
resistant cells was studied using flow cytometry.
Both drugs can enhance intracellular and intranu-
clear accumulation of the model drug doxorubicin.
Both should be considered as effective antitumor
agents and inhibitors of the mechanism of innate or
induced resistance to drugs that are used in com-
bination. Modification of cisplatin administration
may improve response to chemotherapy, but it is
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obvious then that, to maximize platinum inhibi-
tion of ABC-transporter function, the sequence of
drug administration “platinum→multiple drug re-
sistance” should be maintained during the entire
chemotherapy duration.
Clinical-response classification in use during
and/or after neoadjuvant radio- and chemotherapy
is limited by the lack of non-invasive techniques
that allow differentiation between responders and
non-responders. Clinical response by endoscopy,
endoluminal ultrasound (EUS), and/or computed
tomography (CT) cannot differentiate between vi-
able tumor, inflammatory reaction, edema, or scar
tissue, and, in case of endoscopy, it is also investiga-
tor dependent. There are not standardized criteria
such as which positron emission tomography (PET)
parameters recorded should be used. There is a lack
of strict criteria as to which variables under investi-
gationneed tobe included, andpatientmanagement
trials using response as a judgment variable for de-
termining different forms of multimodal treatment
are still missing.Molecular biomarkers and findings
in biogenomics should be used for collating infor-
mation about responses to multimodal therapy.
Response assessment is needed to avoid ineffec-
tive neoadjuvant therapy, with the risk for patients
to be exposed to negative consequences such as
toxicity and delayed surgical therapy.
Fluorodeoxyglucose PET has been used as an ac-
curate diagnostic method for early assessment of
tumor response, but the negative predicting value
is insufficient to apply PET scan for response as-
sessment early in the course of neoadjuvant CRT.
Diffusion-weighted magnetic resonance imaging
(dMRI) might be an alternative with several advan-
tages. Tumor hypoxia could be useful in the identi-
fication of patients whomay benefit from CRT with
specific antihypoxic treatments such as bioreductive
drugs of hypoxic radiosensitizers and, in the future,
a patient-tailored therapy with surgery on indica-
tion after completion of neoadjuvant CRT may be
feasible.
1. Is there any therapeutic reason to
make distinctions in the site of origin
for adenocarcinomas arising slightly
above, slightly below, or at the GEJ?
Andrew C. Chang
andrwchg@umich.edu
Adenocarcinomas arising either in the distal esoph-
agus within 5 cm of the GEJ (Siewert type I) or
at the GEJ (Siewert type II) are typically treated as
esophageal carcinomas, whereas tumors arising in
the gastric cardia within 5 cm of the GEJ (Siewert
type III) are typically treated as gastric carcinomas.1
A preponderance of data reported in the literature
supports the use of multimodality therapy for the
treatment of GEJ adenocarcinomas, albeit largely by
extrapolation. Major therapeutic differences, when
distinguished by tumor location, largely result from
the extent of tumor resection, rather than from any
differences in neoadjuvant or adjuvant treatment
regimens.
In deciding upon operative technique, whether
esophagectomy, gastrectomy, or esophagogastrec-
tomy, treatment planning should consider both the
degree of proximal esophageal involvement and ex-
tent of lymphatic involvement. A proximal tumor-
free esophagealmargin of greater than 5 cm, asmea-
sured in situ, has been associated with improved
overall survival following resection, particularly for
patients whose staging indicates six or fewer in-
volved lymph nodes (N2).2 In a multi-institutional,
international retrospective study of subjects under-
going esophageal resection alone for carcinoma,
the number of resected lymph nodes appeared to
be associated independently with improved overall
survival.3 Furthermore, among patients found to
have eight or more metastatic lymph nodes, nearly
all developed systemic disease within 5 years of
resection.4
In a recent Cochrane systematic review and
meta-analysis,5 perioperative treatment, either
chemotherapy or chemotherapy with concurrent
radiation therapy, provided a statistically significant
overall survival benefit compared to resection alone
for esophagogastric carcinomas, with a hazard ratio
(HR) of 0.81 (95% CI 0.73–0.89) favoring com-
bined modality therapy, as derived from 14 studies
including 2422 subjects. For this analysis, individual
patient data were obtained from relevant published
clinical trials, providing the opportunity to focus
specifically on adenocarcinoma. In sub-group anal-
ysis, patients with GEJ carcinomas (six studies, 470
199Ann. N.Y. Acad. Sci. 1325 (2014) 197–210 C© 2014 New York Academy of Sciences.
Gastroesophageal junction adenocarcinomas Blom et al.
subjects) obtained a survival benefitwith periopera-
tive treatment, with HR 0.69 (0.54–0.87). Although
the benefit of any perioperative treatment regimen
was less apparent for patients with esophageal can-
cers, with HR 0.87 (0.73–1.05), a cohort of patients,
consisting predominantly of those with esophageal
or GEJ carcinomas that had received preoperative
chemoradiation, was found to have a survival ben-
efit, with HR 0.70 (0.50–0.99).
Perioperative treatment regimens predominantly
include platinum-based chemotherapy, regardless
of site of tumor origin,6 and are considered for
more advanced stage tumors (stage IB, II or
worse). For type II or type III AEGs, perioperative
chemotherapywithout radiation therapy is typically
recommended,7 whereas for more proximal AEGs
(Siewert type I or type II), concurrent radiation
therapy can be administered preoperatively8 with
carboplatin and paclitaxel.
2. Combined modality therapy
Trevor Leong
trevor.leong@petermac.org
Currently, the majority of patients with resectable
esophageal cancer are managed with neoadjuvant
therapy before surgical resection. With the excep-
tion of early stage T1–2, N0 disease, most pa-
tients with resectable tumors will be offered ei-
ther preoperative CRT (preop CRT) or preoperative
chemotherapy (preop CT) alone.
Preop CRT
There have been many randomized trials of preop
CRT versus surgery alone. These trials have utilized
a wide variety of radiotherapy dose/fractionation
regimens. Most have employed cisplatin and
5-fluorouracil (5-FU) as the chemotherapy back-
bone. Because these individual trials have shown
conflicting results, several meta-analyses have been
undertaken to evaluate the utility of preopCRT. The
Australasian Gastro-Intestinal Trials Group (AG-
ITG) meta-analysis, which includes data from 13
randomized trials, showed a 22% reduction in all-
cause mortality for preop CRT, which corresponds
to an absolute survival benefit at 2 years of 8.7%.9
The survival benefits for preop CRT were slightly
higher for adenocarcinoma than for SCC, with haz-
ard ratios of 0.75 and 0.80, respectively. The first
study to show a benefit for preop CRT was re-
ported by Walsh et al. in 1996.10 This trial ran-
domized patients with EAC only to either surgery
alone or preop CRT consisting of 5-FU/cisplatin
combined with 40 Gy of radiation. Although this
study showed improved survival with preop CRT,
one of the major criticisms of the trial has been that
survival in the surgery-alone group was very poor,
with only 6% of patients alive at 3 years. The Cancer
and Leukemia Group B (CALGB) study from the
United States is interesting because it is the only one
that has employed a radical radiation dose of 50.4
Gy.11 Although this trial closed early before reaching
its target accrual, it nevertheless showed a survival
benefit for preop CRT. Despite the use of high ra-
diation doses, the surgical complication rates were
similar between the two groups. The largest and
most recent trial is the Chemoradiotherapy for Oe-
sophageal Cancer followed by Surgery StudyCROSS
study from the Netherlands that randomized 368
patients with either SCC or adenocarcinoma to ei-
ther surgery alone or preop CRT.8 The chemoradi-
ation regimen consisted of weekly carboplatin and
paclitaxel combined with 41.4 Gy of radiation. The
5-year survival rates were 47% for preopCRT versus
34% for surgery alone (P = 0.003). The chemora-
diation regimen was extremely well tolerated, and
although the postoperative complication rates were
somewhat higher than expected, there were no sig-
nificant differences between the two groups.
Preop CT
There have been nine randomized trials of preop
CT versus surgery alone. The AGITG meta-analysis
also evaluated the utility of preop CT, and found
improvements when compared to surgery alone, al-
though the treatment effects were not as large as for
preop CRT.9 There was a 13% reduction in all-cause
mortality for preop CT, which corresponds to an
absolute survival benefit at 2 years of 5.1%. A sub-
group analysis by histological subtype showed that
the benefit was statistically significant for adenocar-
cinoma but not for SCC. The principal study sup-
porting the use of preop CT for esophageal cancer is
the Medical Research Council Oesophageal Cancer
Working Group trial (OE2).12 This trial random-
ized 802 patients with either SCC or adenocarci-
noma to either surgery alone or preop CT consist-
ing of two cycles of 5-FU/cisplatin. With a median
follow-up of 37 months, the 2 year survivals were
43% for preop CT versus 34% for surgery alone
(P = 0.004).
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Preop CRT versus preop CT
Which neoadjuvant treatment is superior: preop
CRTorpreopCT?A study reportedbyStahl et al.has
attempted to answer this question.13 This trial ran-
domized 119 patients with adenocarcinoma of the
GEJ to either preop CRT or preop CT. Both groups
received induction chemotherapy with cisplatin/5-
FU/leucovorin. Patients in the CRT group then
received 30 Gy of radiation with concurrent cis-
platin/etoposide. Although the trial was planned to
recruit 354 patients, it was closed early due to poor
accrual. With a median follow-up of 46 months,
the 3-year survivals were 47% for preop CRT versus
28% for preop CT. However, because the study was
closed early before reaching its target accrual, the
improved survival with CRTdid not reach statistical
significance (P = 0.07). The pathological complete
response rate was significantly increased from 2%
for preop CT to 16% for preop CRT (P = 0.03).
The AGITG meta-analysis also compared the sur-
vival benefits of preop CRT versus preop CT.9 The
hazard ratio for all-causemortality was 0.88 in favor
of preop CRT, but again this did not reach statisti-
cal significance (P = 0.07). In summary, there are
two alternative standards of care for neoadjuvant
therapy in esophageal cancer; preop CRT, which is
usedmainly inNorthAmerica, andpreopCT,which
is used mainly in the United Kingdom. Ongoing
studies are evaluating the role of PET and molecu-
lar biomarkers to predict response to neoadjuvant
treatment.
3. Tumor markers for use in personalized
medicine
Paul E. Swanson
paul.swanson@cls.ab.ca
The complexity of molecular pathways in human
neoplasms is astounding, and the potential role
of mutational, epigenetic, or other molecular
alterations in these pathways as biomarkers for
diagnosis, prognosis, and prediction of global
and targeted therapeutic interventions is similarly
complex. A surprising number of these receptor
and pathway effector molecules already have both
specific antibody and small-molecule inhibitor
pharmacologic agents ready for preclinical eval-
uation and immediate clinical applications. Yet,
few currently recognized prognostic or predictive
markers have clear evidentiary support for their
use in the emerging practice of personalized
medicine.14 The challenge rests in identifying
specific molecular markers that are reproducibly
associated with disease progression or that serve as
robust predictors of treatment response. Dissecting
molecular pathways to identify common genetic
or chromosomal alterations provides a reservoir of
markers of interest, but translating these markers
into safe and effective clinical interventions remains
elusive.
In both EAC and SCC, recent exomic and ge-
nomic sequencing analyses have strengthened the
objective foundation for the importance of selected
molecular pathways to the genesis and progression
of disease.15,16 These studies also reiterate that the
repertoires of abnormalities in critical genes and
gene pathways differ substantially between diagnos-
tic groups, while emphasizing that multiple path-
ways may be altered within diagnostic groups. This
intrinsicheterogeneitymakes it likely that evencom-
monly encountered abnormalities will only be rel-
evant to the treatment of selected populations of
EAC and SCC patients and that combinations of
biomarkers and therapeutic targets will have the
greatest impact onmanagement of a given patient or
patient cohort. With that in mind, it will be neces-
sary to understand interactions between pathways
to fully appreciate the predictive value of selected
markers.
Pathways and markers of interest
In EAC, a variety of molecular pathways have been
targeted formolecular analysis and clinical interven-
tion. Perhaps themost important of these in current
practice is MAP kinase, associated with tyrosine ki-
nase receptors and downstream effectors through
KRAS and BRAF. The two most common targets
(used now in esophageal neoplasms after their po-
tential utility was established in other sites) are
HER2 and EGFR.16–19 HER2 is of interest because
amplification of this genetic locus (Fig. 1) is associ-
ated with overexpression of the functional receptor,
establishing it as a target for intervention,while both
EGFRmutation and amplification may be of signif-
icance in EAC and SCC. The ToGA trial,18 together
with preliminary studies of esophageal neoplasms,
suggest that the expected positive rate forHER2 am-
plification ingastric,GEJ, andEAC isnogreater than
20–25%, and that the clinical response to combined
anti-HER2 and chemotherapy in HER2-amplified
201Ann. N.Y. Acad. Sci. 1325 (2014) 197–210 C© 2014 New York Academy of Sciences.
Gastroesophageal junction adenocarcinomas Blom et al.
Figure 1. Demonstration ofHER2 gene amplification in esophageal adenocarcinoma by fluorescent in situ hybridization. In this
image, orange signals identify copies of the HER2 gene on chromosome 17, while the green signals identify centromeric elements
of this chromosome, using the Cep17 probe. The Her2:Cep17 ratio in this case is 5.9 (Her2:Cep17 fluorescent in situ hybridization;
600×).
neoplasms is significant. Interestingly, this predic-
tive role for HER2 is not accompanied by a simi-
lar value in risk stratification, since neither HER2
nor EGFR status in EAC reliably predicts prognosis
independent of anticipated treatment effect. Unfor-
tunately, adverse clinical effects of antibody-based
treatments to these receptor moieties––especially
EGFR––are potentially limiting in both EAC and
SCC.17
The importance of the pTEN tumor suppres-
sor, through its inhibitory effects on the PI3K–Akt–
mTORpathway, has been independently established
in a subset of EAC.19 However, because its clinical
significance relies on loss of function through mu-
tation or epigenetic alteration, attention shifts to
downstream elements of the pathway, where (phos-
pho)Akt and mTOR emerge as more interesting
therapeutic targets. pTEN also serves as a model
for interactions across pathways that mitigate (or
potentially augment) the clinical effectiveness of
targeted therapies. A recent analysis by Eto et al.
demonstrated that the microRNA-21–pTEN path-
way selectively regulates tumor responsiveness to
trastuzumab in gastric carcinoma,20 an observation
that has not yet been extended to EAC.
The role of small-molecule inhibitors in counter-
acting themolecular effects of epigenetic alterations
in the canonical Wnt signaling pathway is also in-
triguing, when interventions for EAC and SCC are
compared to thoseproposed for cancermodelsmore
dependent onmutational alterations in the pathway
(suchas colorectal carcinoma).Chemotherapies tar-
geting EAC and SCC populations identified asMSI-
high––often due to epigenetic effects (primarily
CpG-island methylation of the upstream promot-
ers of mismatch-repair genes) and more common
in SCC than EAC21––are also relevant to modern
oncologic management.
Markers that stratify risk for tumor pro-
gression include (but are clearly not limited
to) VEGF-C/VEGFR14–17,22 (in both EAC and
SCC), TP53, NF-B, TGF-/SMAD4, RUNX3, and
GATA6/BMP4, the latter five best illustrated in BE-
associated dysplasia and EAC.14 Notch signaling is
also potentially important to both EAC and SCC,
with loss of SMAD4 inhibition seen in EAC16 and
loss of function due to mutation in SCC.15 Fi-
nally, novel and potentially useful biomarkers as-
sociated with progression from BE dysplasia to EAC
have been identified in large-scale genomic15,16 and
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serum glycomic analyses.23 These include the Rac
pathway proteins ELMO1 and DOCK2 (implicated
in cell motility and stromal invasion);15 fetuin B, a
cystatin modestly upregulated in BE–HGD (high-
grade dysplasia) and significantly increased in EAC;
and elastin microfibril interface located protein 2
(EMILIN-2), an extracellular matrix glycoprotein
that is involved in activation of the extrinsic pathway
of apoptosis, inhibits cell growth, and is increased
in HGD and EAC relative to disease-free controls.23
Conclusions
Analyses of genetic and epigenetic alterations in
EAC and esophageal SSC and their precursor le-
sions have identified a number of possible targets
for treatment. However, several constraints, includ-
ing the degree of heterogeneity for these markers
within target populations and the as yet poorly un-
derstoodnature of the interactions of different func-
tional pathways on treatable foci, complicate––even
obfuscate––our attempts to determine the relative
importance of a given biomarker to both risk as-
sessment andpatientmanagement.Nonetheless, the
yield from increasingly powerful techniques avail-
able for novel marker discovery drive optimism that
the reality of individualized targeted therapy (per-
sonalized medicine) may begin to approach the an-
ticipated potential of patientmanagement in the era
of molecular medicine.
4. Evaluation of response to neoadjuvant
chemoradiotherapy in esophageal
cancer using multimodality imaging
Peter S.N. van Rossum, Richard van Hillegersberg,
and Jelle P. Ruurda
P.S.N.vanRossum2-@umcutrecht.nl
CRT followed by surgery has become the current
standard of treatment for patients with resectable
esophageal cancer.8 This regimen has increased the
percentage of microscopic radical resections up to
92%, as opposed to 69% in the surgery-only control
group. Furthermore, the 5-year survival and me-
dian survival improved by 13% and 25.4 months,
respectively. Interestingly, a pCR was found in 29%
of neoadjuvantly treated patients. This absence of
residual cancer in the resection specimen is an im-
portant independent prognostic factor, and it has
been speculated that surgery might be omitted in
this selected group of patients in the future. On the
contrary, approximately 20% of patients in the CRT
arm of the trial showed a pNR. These patients suffer
from ineffective toxic CRT, and probably surgery is
unnecessarily delayed. Early identification of pCR
or pNR during or after neoadjuvant treatment is of
clinical importance to reduce toxicity and improve
personalized patient care.
Multiple studies describe the value of differ-
ent imaging modalities in the evaluation of re-
sponse to neoadjuvant treatment as compared to
the gold standard of histopathological tumor regres-
sion. With regard to this matter, negative predictive
values (NPVs) of a test are of particular interest, as
these refer to the likeliness of a suspected complete
response—based on the test result in an individ-
ual patient—to truly reflect pCR. With pre- and
post-treatment endoscopies, poor NPVs of 31–44%
are found, and these do not significantly improve
by adding biopsies.24,25 The underlying submucosal
extent of the residual tumor can be masked by a
normal-appearing lumen, and sampling errors oc-
cur as deep and spread residual foci as well as re-
maining metastatic lymph nodes that can be easily
missed. Furthermore, in cases of residual disease
endoscopy with or without biopsies, it is not possi-
ble to distinguish non-responders from partial re-
sponders. Other studies looked into one- or two-
dimensional size measurements using EUS. Dis-
appointingly, reported NPVs varied from 17% to
69%.25–27 Themain limitation of EUS is overstaging
attributable to the difficulty of differentiating fibro-
sis and inflammation from residual tumor. Further-
more, EUS is an invasive technique, with a known
failure rate of 13–25% due to stenotic tumors.
Studies on repeated CT for response evaluation
were pooled in a systematic review that reported a
maximum joint sensitivity and specificity of only
54%.28 In a 3-D CT study, the tumor volume in re-
sponders was found to paradoxically increase over
time owing to inflammation and fibrosis, implying
that dimensional criteria alone cannot be trusted for
response evaluation.29 Therefore, metabolic assess-
ment rather than spatial assessment may be help-
ful. In the past decade, PET and combined PET–CT
studies were performed for this reason. A systematic
review and meta-analysis reveal a pooled sensitiv-
ity and specificity of around 70%.30 Available PET
studies are heterogeneous and mostly single center
and there is a need for standardization of protocols
and well-designed multicenter trials. New develop-
ments that could potentially improve the value of
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PET–CT include combining spatial and metabolic
information and using computer-based compre-
hensive spatial–temporal features.
Since all currently studied modalities yield un-
satisfactory results in the assessment of response to
neoadjuvant treatment in esophageal cancer so far,
there might be a need for a new, more accurate tool.
Diffusion-weighted imaging (DWI) is a functional
MRI technique that derives its image contrast from
differences in the motion of water molecules be-
tween tissues. Tumor tissue shows low free-water
diffusion owing to the high cellularity and intact
cell membranes. But as tumor cells die from treat-
ment (e.g., show a response), cellularity decreases,
resulting in an increase of free diffusion of water
molecules. In rectal cancer, it was already shown
that pathological complete responders tend tohave a
high increase of diffusion over time.31 Although this
relatively newmodality has beenproven to be excep-
tionally valuable for treatment-response assessment
in rectal cancer, its application in esophageal cancer
hashardlybeen explored.32 Therefore, at theUniver-
sity Medical Center Utrecht (the Netherlands) the
PRIOR trial was designed as an explorative single-
center diagnostic study to assess both the distinct
and combined value of advancedMRI and PET–CT
scanning in the evaluation of treatment response
to neoadjuvant CRT for patients with esophageal
cancer.
In the past year, in Utrecht, anMRI-optimization
study was conducted in 20 patients in order to opti-
mize scan parameters for both anatomical and func-
tional MRI sequences including T1/T2-weighted
imaging, DWI, and dynamic contrast-enhanced
MRI (DCE-MRI). Imaging quality, protocol robust-
ness, and reproducibility were optimized and ge-
ometrical disturbances and motion artifacts were
reduced. So far, preliminary results from pre- and
post-treatmentDWI scans andhistopathological as-
sessment of tumor regression indicate promising
results. The scan parameters derived from this opti-
mization study will be used in the actual treatment
response study: the PRIOR trial, which is currently
ongoing. In the PRIOR trial, 30 patients with re-
sectable esophageal cancer receiving neoadjuvant
CRTbefore surgerywill undergo advancedMRI and
PET-CT scans before, during, and after neoadjuvant
treatment. All images will be co-registered using
sophisticated deformable image-registration algo-
rithms, allowing voxel-by-voxel analysis of all image
modalities over all three timepoints for eachpatient.
Imaging response measurements will be compared
with the histopathological tumor regression in the
resection specimen as the gold standard.
In conclusion, current imaging lacks accurate as-
sessment of response to neoadjuvant treatment in
esophageal cancer. PET-CT seems the best modality
so far, while MRI is a promising new tool, as sug-
gested by rectal cancer studies and our preliminary
experience in esophageal cancer. The PRIOR trial
will be the first study worldwide to explore the dis-
tinct and combined value of advanced anatomical
and functionalMRI andPET-CT techniques for this
purpose. Ultimately, machine-learning techniques
will be applied to develop a multiparametric model
that accurately model that accurately predicts re-
sponse based on multimodality imaging.
5. Is there a standardized grading system
for tumor regression in SCC and in
adenocarcinoma?
Xavier Sagaert
xavier.sagaert@uzleuven.be
Esophageal cancer is the 8th most common can-
cer worldwide, and more than 80% of cancers oc-
cur in less developed countries. There are various
subtypes, primarily SCC (approximately 90–95%
of all esophageal cancer worldwide) and EAC (ap-
proximately 50–80% of all esophageal cancer in the
Western world). Esophageal squamous cell cancer
mainly occurs in the so called “Asian belt” and arises
from the non-keratinizing stratified squamous ep-
ithelium that lines the esophagus. Adenocarcinomas
of the esophagus and the GEJ are the most dra-
matically rising cancers in the Western world and
arise froma single layer of columnar, usuallymucus-
secreting, epithelium that is present at the junction
of the esophagus and stomach (a process called Bar-
rett’s metaplasia). Importantly, SCCs are associated
with heavy tobacco and alcohol consumption, while
adenocarcinomas are often associated with a his-
tory of gastroesophageal reflux disease (GERD) and
Barrett’s esophagus (BE).
To improve the outcome of this malignancy with
an already very bad overall prognosis, esophageal
cancers infiltrating beyond the mucosa are mostly
treated by neo-adjuvant CRT before invasive
and extensive surgery.7,33 Remarkably, while 20%
of patients will reach a complete pathological
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complete response after CRT, in about 30–50% of
patients no measurable response will be achieved
at all.34 While a predictor of response/resistance to
CRT at diagnosis (that could save responding pa-
tients from invasive surgery and avoid the toxicity
of unnecessary CRT and delay of surgery in non-
responding patients) has not been identified yet,
it is generally believed that histological tumor re-
gression after chemotherapy is an important objec-
tive parameter that has prognostic value in several
studies.
The prognostic significance of the histopatho-
logical response to cytotoxic therapy in esophageal
cancer specimens (predominantly SCC) was first
reported by Mandard et al.35 Tumor regression
grade (TRG) analysis, as a marker of treatment re-
sponse, was undertaken in that study and scored
from complete regression (TRG1) to absent re-
gression (TRG5). In brief, TRG1 (complete re-
gression) showed absence of residual cancer and
fibrosis extending through the different layers of
the esophageal wall; TRG2 was characterized by
the presence of rare residual cancer cells scattered
through the fibrosis; TRG3 was characterized by an
increase in the number of residual cancer cells, but
fibrosis predominated; TRG4 showed residual can-
cer outgrowing fibrosis; and TRG5 was character-
ized by the absence of regressive changes. Of the 93
cases in the study, 42% were TRG1–2, 20% TRG3,
and 33% were TRG4–5. Tumor size, pathological
lymph node status, TRG, and esophageal wall in-
volvement correlated highly with DFS. On multi-
variate analysis, however, only TRG (TRG1–3 versus
TRG4–5) remained a significant (P < 0.001) pre-
dictor of DFS. However, while the Mandard TRG
is highly prognostic and remains universally the
most widely used regression system in esophageal
cancer, it has not been validated in adenocarcino-
mas and has been shown to suffer from high inter-
observer variability. Hence, other grading scoring
systems have been introduced, although they are
not widely used. Of particular interest, Langer et al.
applied a three-score tumor regression system for
EAC that was originally introduced for gastric can-
cer (albeit slightly modified), similar to a score that
they also successfully applied to esophageal squa-
mous carcinomas and rectal cancer.36 These three-
tiered regression scoring systemshave alsobeenused
for larger retrospective studies by others, as they
seem to be more easily implemented, more repro-
ducible, stronger, and clearer with regard to prog-
nostic impact.37,38 Langer et al. even demonstrated
that these three-tiered histological TRG systems that
score the effects of preoperative chemotherapy in
esophageal cancer provided highly valuable prog-
nostic information, which may even exceed the
prognostic impact of the current TNM classifica-
tion of these tumors.
In conclusion, despite tons of data and its prog-
nostic significance, no generally accepted standard-
ized clinical or histopathological response evalua-
tion systemhas been established so far.Nevertheless,
it is strongly recommended that there be implemen-
tation of a standardized tumor regression-grading
system in pathological reports of EAC treated by
neoadjuvant chemotherapy.
6. Experimental and clinical basis for
optimization of cisplatin administration
schedule to improve chemotherapy
efficacy in patients with locally
advanced esophageal cancer
Tatiana Bogush, Evgeny Dudko, Boris Polotsky,
Sergei Tjulandin, and Mikhail Davydov
labmedchem@mail.ru
Background
It is commonly accepted that chemotherapy has un-
satisfactory effects in patients with esophageal can-
cer, and approaches to increase treatment efficacy
are developed intensively. Studies investigating this
problem demonstrated that MDR phenotype, as-
sociated with expression of energy-dependent ABC
transporters extruding MDR drugs out of the cells,
was found in most esophageal cancer cases.39–41 At
the same time, the role of ABC transporters in the
mechanism of multiple drug resistance to most an-
titumor agents used in the clinical practice has been
scientifically proven. The idea of studying platinum
drugs as polyvalent MDR inhibitors acting on var-
ious ABC transporters’ functioning emerged in at-
tempts to determine why MDR tumors responded
to MDR cytostatics in combination with platinum
derivatives. This clinical fact is well documented in
the treatment of cancers of different sites, including
esophageal tumors.
We have tried to explain this phenomenon on the
basis of platinum properties described in the litera-
ture (i.e., binding to ATP that is needed for energy-
dependentABCtransporters to functionand tobind
to various proteins).42 If this is true, then it is log-
ical to assume that platinum agents inhibit ABC
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transporter function and, as a result, overcome or
reduce MDR to MDR agents used in combination
with platinum. Direct experiments proved this as-
sumption true.
Experimental investigation
The influence of cisplatin and carboplatin on in-
tracellular accumulation of the model MDR drug
doxorubicin in MDR cells was studied using flow
cytometry.43 It was demonstrated that the platinum
derivatives inhibited ABC transporter function.44
Both drugs can enhance intracellular and, what
is still more important, intranuclear accumulation
of the model MDR drug doxorubicin. This means
that cisplatin and carboplatin should both be con-
sidered effective antitumor agents and inhibitors
of the mechanism of innate or induced resistance
to MDR drugs that are used in combination with
them. In fact, this is an explanation of the above-
mentioned phenomenon of increased efficacy of
platinum agents in combination with inactiveMDR
cytostatics in treatment of esophageal cancer. Our
own clinical experience may be a positive example
demonstrating the efficacy of this approach.
Clinical pilot investigation
Design. Thirty-six patients with locally advanced
esophageal cancer receivedpreoperative chemother-
apy with cisplatin, etoposide, 5-FU, leukovorin
(FLEP); cisplatin being administered by standard
schedule with cisplatin administered on day 1, or
by a modified schedule, with cisplatin given on days
1–3. The remaining drugs were always given on a
daily basis, with etoposide administered in modi-
fied schedule after cisplatin. The two treatment arms
were well balanced by main clinical characteristics.
Response was assessed after two 3-day cycles with a
3-week interval.
Results. The number of cases demonstrating de-
creased severity of dysphagia after completion of
chemotherapy was greater in themodified-schedule
group (43% vs. 24% of cases), although there were
morepatientswithhigher dysphagia intensity in this
group at baseline (19% vs. no patients with grade
III dysphagia). More patients receiving a modified
FLEP regimen as compared to the standard regimen
group demonstrated decrease (60% vs. 48%) or no
change (40% vs. 26%) in disease extent by x-ray af-
ter chemotherapy completion. Complete responses
(20%of cases) were shown in themodified-regimen
group only, and no patients in that group had pro-
gressive disease, versus 26%of caseswithprogressive
disease in the standard-regimen group. And finally,
more patients receiving modified FLEP survived
1 year of follow-up (79% vs. 65%).
Conclusion. Although these findings are but in-
terim, we nevertheless believe that modification of
cisplatin-administration schedule alone may im-
prove response to chemotherapy with MDR drugs
in theMDR-resistant patient category because plat-
inum drugs are inhibitors of the mechanism of
innate or induced MDR. In particular, the results
demonstrate proof in the principal efficacy of this
approach on the example of the modified sched-
ule of FLEP chemotherapy in patients with locally
advanced esophageal cancer.
It is obvious, then, that tomaximize platinum in-
hibition of ABC-transporter function, the sequence
of drug administration “platinum→ MDR drugs”
should be maintained during the entire chemother-
apy duration. It is not always so in routine clin-
ical practice, because sequence of administration
of platinum derivatives and other cytostatics is not
strongly established. We consider this detail to be
of much importance, and think that it should be
controlled in the clinical practice to ensure maxi-
mum therapeutic effect of MDR drugs in combina-
tion with platinum derivatives in the treatment of
MDR-tumors including esophageal cancer.
[Supported by Russian Foundation for Basic
Research Grants (No.13-04-01004-а, No. 12-04-
00028-a) and Grant of the President of the Russian
Federation (No. 376.2012.4).]
7. Are criteria measuring response in
esophageal cancer appropriate?
Bjo¨rn L.D.M. Bru¨cher
bbruecher-@gmx.de
Introduction
The actual response criteria have recently been
reviewed.45 These criteria have been in use since
1981 and, according to these criteria, response to
anticancer treatment has been defined as being a
therapy-induced change of two perpendicular pa-
rameters in size by at least 50%.46 One of the first
suggestions that diameters beused formeasuring re-
sponse was proposed in 1966,47 with the subsequent
experiment of Moertel and Hanley in 1976:48 16 ex-
periencedoncologists receiveddifferent sizesof solid
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wooden spheres covered with a layer of rubber foam
and were tasked with judging the change in size.
An error of 50% resulted in 6.8% false positive,48
which in turn resulted in the recommendation that
only complete or partial response should be used
in the determination of the response to anticancer
therapy.49 Subsequently, a 2-Dmeasurement of one
dimensionwas replacedby thedecreaseof the largest
tumor diameter by 30%, interpreting this as equiv-
alent to a 50% decrease for a spherical lesion.50 As
during the 1970s no standardized way of describing
and/or judging response was available, the primary
goal was necessary.
It has been shown that clinical response by en-
doscopy, EUS, and/or CT cannot differentiate be-
tween viable tumor, inflammatory reaction, edema,
or scar tissue and, in case of endoscopy, it is also in-
vestigator dependent.51 Until now, histopathologi-
cal response assessing the percentage rate of residual
tumor cells hasminimized potential errors owing to
the known post-therapeutic heterogeneity.52 Newer
methodological approaches include the use of flu-
ordeoxyglucose PET (FDG-PET).28,53 However, a
major challenge is that no standardized criteria such
as which PET parameters recorded should be used:
(e.g., difference of a PET investigation before and
after a multimodal approach (SUV), SUVmean or
SUVmax, or even aSUVmax). Another point of in-
terest is that journals do not demand strict criteria
as to which variables under investigation need to
be included, and some groups provide all necessary
data including sensitivity, specificity, positive, and
negative predictive value (PPV, NPV), and overall
accuracy, including 95% confidence intervals (CI),
while others do not.53 This is further complicated
by the fact that there is no regulation in terms of
different inclusion criteria: different histological en-
tities (different tumor biology, ways of metastasis,
and prognosis), different surgical approaches (dif-
ferent postoperative outcomes), differences in delay
of response measurement, or difference in training
and standardization of histopathological workup.
Also, the increase in survival during implementa-
tion of neoadjuvant trials was performed in an area
in which the operative procedures were standard-
ized. This argument was clearly shown by the lead-
ing upper GI centers in the 1990s, revealing that the
outcomes of patients treated during the 1980s was
statistically significantly worse than that obtained
in the 1990s.53 Furthermore, patient management
trials using response as a judgement variable for de-
termining different forms of multimodal treatment
are still missing.
Although these factors have not been resolved
to date, groups and companies have already
declared that molecular biomarkers and findings
in biogenomics should be used for collating
information about responses to multimodal ther-
apy. To date, no group has been able to provide
the necessary scientific information for judging
these biomarkers in terms of the half-life time of
each biomarker, its daily changes in concentra-
tions/activities, or how the determination should
be standardized. Additionally, basic findings in
biogenomics are also missing, which could serve
as a standard for being included within a new
response classification. Comparing tumors with
different anatomy, embryology, and histology that
reveal different tumor biologies makes the task of
standardization even more complicated.
In upper-GI cancer, clinical response classi-
fication in use during and/or after neoadjuvant
radio- and chemotherapy is limited by the lack of
non-invasive techniques that allow differentiation
between responders and non-responders. Addi-
tionally, the classification system for evaluating
response needs to be revisited.
8. The impact of novel imaging on
staging and response assessment
Marie-Celine Schraepen, Rachel L.G.M. Blom,
Meindert N. Sosef
meindert.sosef@me.com
Introduction
Esophageal cancer is the sixth leading cause of
cancer death worldwide, with 500,000 new cases
each year. Survival rates for both M0 and M1
esophageal cancer in the Netherlands have shown
steady improvements over recent decades.54 This
may be due to centralization, resulting in improved
patient selection, perioperative care, and surgical
experience. A recent development is the introduc-
tion of neoadjuvant chemoradiation, which has
led to an improved oncological outcome and an
increased overall survival rate compared to patients
who underwent surgery alone.55
Staging is needed to avoid palliative surgery
Esophageal cancer is known for its early dissemina-
tion. On diagnosis, at least half of the patients have
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locally advanced or metastatic disease. According to
the American Joint Committee on Cancer (AJCC),
CT, PET, and integrated PET-CT are included in
the staging techniques to establish the M-stage in
esophageal cancer.56
Metastatic disease after completion of neoad-
juvant CRT implies that curative treatment is
no longer possible; thus, accurate patient selec-
tion is crucial. Several studies have described
post-neoadjuvant therapy metastases in 8–17% of
patients.57,58 Routine PET-CT after completion of
theneoadjuvant therapy is recommended in thepre-
vention of palliative resections.56
Response assessment is needed to avoid
ineffective neoadjuvant therapy
As previously mentioned, neoadjuvant CRT before
surgery can improve the oncological outcome of pa-
tients; however, not all patients show a response to
neoadjuvant therapy. Non-responders do not ben-
efit from neoadjuvant CRT but are exposed to the
negative consequences such as toxicity and delayed
surgical therapy.
FDG-PET has been used as an accurate diagnos-
tic method for early assessment of tumor response
in malignant lymphoma and non-small cell lung
cancer to CRT.59 In esophageal cancer patients, a
decrease in SUV, measured by FDG-PET before and
14 days after the start of CRT, was associated with
a histopathological response. The negative predict-
ing value was insufficient to apply FDG-PET for
response assessment early in the course of neoadju-
vant CRT.59
Diffusion-weighted magnetic resonance imag-
ing (DW-MRI) might be an alternative to FDG-
PET. DW-MRI has several advantages compared to
FDG-PET. Before DW-MRI is performed, fasting
is not necessary; furthermore, no exogenous con-
trast material is required. However, preliminary re-
sults showed no correlation between pretreatment
tumor apparent diffusion coefficient (ADC) and
change in tumor ADC 10 days after the start of
chemoradiotherapy.60
Tumor hypoxia is an important marker of can-
cer prognosis, because of its association with ag-
gressive growth, resistance to anticancer therapy,
and metastases.61 Therefore, tumor hypoxia could
be useful in the identification of patients who
may benefit from CRT with specific antihypoxic
treatments such as bioreductive drugs of hypoxic
radiosensitizers.62 Quantification of tumor hypoxia
can be calculated by performing non-invasive PET
imaging with hypoxia-specific 2-nitroimidazoles.
This type of imaging needs further investigation to
determine optimal imaging conditions.62
Surgery on indication
In the future, a patient-tailored therapywith surgery
on indication after completion of neoadjuvant CRT
may be feasible. Patients will need to undergo close
surveillance after completion of neoadjuvant ther-
apy. Only patients in whom a locoregional recur-
rence is highly suspected or proven, without any
signs of distant dissemination, will be offered a sur-
gical resection.63
Conclusion
In esophageal cancer treatment, neoadjuvant
chemotherapy leads to an increase in overall
survival.55 Accurate patient selection is crucial
for a curative treatment. Response assessment in
esophageal cancer is promising but needs to be fur-
ther investigated before it can be implemented.
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